S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Is AMC Entertainment Pulling a Fast One on the APEs?
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Boredom, loneliness plague Ukrainian youth near front line
High oil prices help Saudi Aramco earn $88B in first half
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Here’s How the Inflation Reduction Act Energizes Power Stock
Average US gasoline price falls 45 cents to $4.10 per gallon
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Is AMC Entertainment Pulling a Fast One on the APEs?
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Boredom, loneliness plague Ukrainian youth near front line
High oil prices help Saudi Aramco earn $88B in first half
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Here’s How the Inflation Reduction Act Energizes Power Stock
Average US gasoline price falls 45 cents to $4.10 per gallon
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Is AMC Entertainment Pulling a Fast One on the APEs?
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Boredom, loneliness plague Ukrainian youth near front line
High oil prices help Saudi Aramco earn $88B in first half
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Here’s How the Inflation Reduction Act Energizes Power Stock
Average US gasoline price falls 45 cents to $4.10 per gallon
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Is AMC Entertainment Pulling a Fast One on the APEs?
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Boredom, loneliness plague Ukrainian youth near front line
High oil prices help Saudi Aramco earn $88B in first half
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Here’s How the Inflation Reduction Act Energizes Power Stock
Average US gasoline price falls 45 cents to $4.10 per gallon
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
NASDAQ:ATXI

Avenue Therapeutics - ATXI Stock Forecast, Price & News

$0.29
0.00 (-0.93%)
(As of 08/12/2022 09:14 PM ET)
Add
Compare
Today's Range
$0.27
$0.29
50-Day Range
$0.22
$0.32
52-Week Range
$0.20
$1.85
Volume
88,100 shs
Average Volume
2.21 million shs
Market Capitalization
$6.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Avenue Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
0.81mentions of Avenue Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

ATXI stock logo

About Avenue Therapeutics (NASDAQ:ATXI) Stock

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Avenue Therapeutics Stock Performance

Shares of ATXI Stock remained flat at $0.29 on Friday. The company had a trading volume of 88,115 shares, compared to its average volume of 178,918. Avenue Therapeutics has a one year low of $0.20 and a one year high of $1.85. The company has a 50-day simple moving average of $0.27 and a 200 day simple moving average of $0.41.

Avenue Therapeutics (NASDAQ:ATXI - Get Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.14) earnings per share (EPS) for the quarter.

Receive ATXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATXI Stock News Headlines

SL Green Announces Sale of 609 Fifth Avenue
Abeona adds new CFO from Avenue Therapeutics
Avenue Therapeutics Stock Trading Halted Today
Avenue Therapeutics, Inc. Common Stock (ATXI)
See More Headlines
Receive ATXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATXI Company Calendar

Last Earnings
11/14/2021
Today
8/15/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATXI
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-3,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.18 per share

Miscellaneous

Free Float
20,863,000
Market Cap
$6.28 million
Optionable
Not Optionable
Beta
0.96














ATXI Stock - Frequently Asked Questions

How have ATXI shares performed in 2022?

Avenue Therapeutics' stock was trading at $0.9080 at the beginning of the year. Since then, ATXI stock has decreased by 68.2% and is now trading at $0.2890.
View the best growth stocks for 2022 here
.

When is Avenue Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our ATXI earnings forecast
.

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) posted its quarterly earnings results on Monday, May, 16th. The company reported ($0.14) earnings per share for the quarter.

What other stocks do shareholders of Avenue Therapeutics own?

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

Who are Avenue Therapeutics' major shareholders?

Avenue Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.57%). Insiders that own company stock include Elizabeth Garrett Ingram, Joseph Walter Vazzano and Neil Herskowitz.
View institutional ownership trends
.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $0.29.

How much money does Avenue Therapeutics make?

Avenue Therapeutics (NASDAQ:ATXI) has a market capitalization of $6.28 million.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The official website for the company is www.avenuetx.com. The company can be reached via phone at (781) 652-4500 or via email at ir@avenuetx.com.

This page (NASDAQ:ATXI) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.